← All trials
NCT07217379
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2025
- Primary completion
- Dec 31, 2026
- Completion date
- Feb 28, 2027
- First posted
- Oct 16, 2025
- Last posted
- Oct 16, 2025
- Enrollment
- 24
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of North Carolina at Chapel HillLead sponsor
- Henry M. Jackson Foundation for the Advancement of Military MedicineCollaborator
- United States ArmyCollaborator
- University of North Carolina at Chapel HillOfficial
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- Department of DefenseCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.